title: ImmTACs: Novel bi-specific agents for targeted cancer therapy.
abstract: Our expanding knowledge of the immune system is guiding a new era of targeted anticancer therapies. Here, we describe our recent work on a novel class of anticancer agents termed ImmTACs. These molecules combine the power of picomolar-affinity TCR-based antigen recognition with the immune-activating potential of an anti-CD3 antibody fragment, to potently redirect T-cell killing to tumor cells.
authors.affiliation: Immunocore Ltd; Abingdon, UK.
authors.forename: Joanne
authors.initials: J
authors.lastname: Oates
authors.forename: Bent K
authors.initials: BK
authors.lastname: Jakobsen
keywords: CD3; ImmTAC; T cell receptor; immunotherapy; thymic selection